Is Thymosin Alpha-1 Legal in New York? How to Access It Legally

HealthRX.com

Thymosin alpha-1 is not FDA-approved and is in no state pharmacy list

Print or save as PDF

  • FDA approval / None. No US marketing application; four orphan designations are not approvals [1]
  • State-licensed pharmacy list / Not in any category; FDA proposed against adding it [2][4]
  • Outsourcing facility list / Category 3, 'nominated without adequate support' [3]
  • Federal advisory vote / 4 yes, 17 no on both the free base and the acetate, December 2024 [4]
  • HHS October 2026 draft policy / Not among the six peptides it names [5]
  • Approved outside the US / Italy, India and Hong Kong, per FDA [1]
  • Sport / Not named on WADA's 2026 Prohibited List [6]

What its US status is

Thymosin alpha-1 (thymalfasin) is a 28-amino-acid peptide with an acetylated N-terminal end, originally isolated from thymosin fraction 5. Zadaxin is the brand of the finished 1.6 mg injection sold outside the US, and it is not interchangeable with bulk thymosin alpha-1 powder [1]. It is a different peptide from thymosin beta-4 and TB-500 [6].

A Drugs@FDA search found no US marketing application for it, and its four orphan drug designations are a separate process, not approvals [1]. FDA lists national authorisations in Italy (adjuvant to influenza vaccination in immunocompromised people), India (chronic hepatitis B in adults 18 or older with compensated liver disease and virus replication) and Hong Kong [1]. The European Medicines Agency holds only an orphan designation, for hepatocellular carcinoma, which is not a marketing approval [1]. Two older reviews by authors tied to the Zadaxin developer say it is approved in 'over 35 countries' (2009) and 'more than 30 countries' (2007) [7][8].

Questions worth asking

Choose the questions you want to keep

Can a New York pharmacy compound it?

Thymosin alpha-1 is not in any of the three categories on FDA's list for state-licensed pharmacies and physicians (updated 14 May 2026) [2]. On the outsourcing facility list (updated 21 March 2025) it is in category 3, 'nominated without adequate support', and FDA's category 1 policy of generally not acting against compounders does not apply to it [3][2]. On 4 December 2024 the Pharmacy Compounding Advisory Committee voted 4 yes and 17 no, with no abstentions, on both the free base and the acetate. Members who voted no cited no compelling evidence of clinical effectiveness and safety, and FDA proposed that it not be added to the pharmacy list [4].

Thymosin alpha-1 was previously in category 2 (significant safety risks) and now sits in FDA's 'nominated but withdrawn' table because the nominators withdrew it [9]. FDA still posts its concerns: immunogenicity risk for certain routes of administration, peptide-impurity and characterisation problems, and safety information the agency called inadequate to understand the extent of any safety issues [9]. Thymosin alpha-1 is also not among the six peptides named in HHS's October 2026 draft enforcement-discretion policy, which lists BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500 [5].

Is it prohibited in sport?

Thymosin alpha-1 is not named on WADA's 2026 Prohibited List [6]. WADA does name thymosin-beta-4 and its derivatives such as TB-500 under S2.3 growth factors, which is a different peptide. The S0 catch-all covers only substances with no approval from any governmental health authority, and thymosin alpha-1 is approved in some countries [6][1].

What is known about dosing and safety

No US-approved dose exists. In Italy, the Zadaxin 1.6 mg finished injection is labeled for subcutaneous or intramuscular use twice weekly for 4 weeks starting at the first vaccination, repeated from week 8 to week 12 at the second vaccination. That is an Italian regimen for the branded product, not a dose for compounded or bulk thymosin alpha-1. The Italian label says it is not for children, is contraindicated in pregnancy and breastfeeding, and calls for caution in people with allergies or autoimmune disease and with other immune-modulating drugs [1].

A 2026 Cochrane review of 10 randomised trials in 1,349 adults with chronic hepatitis B rated the evidence very low certainty, and the reviewers said they were 'not sure' thymosin alpha-1 helps [10]. The review found thymosin alpha-1 may have caused fewer serious adverse events than comparison treatments (risk ratio 0.72, 95% CI 0.53 to 0.99; 5 trials, 1,056 people; low-certainty evidence) [10].

Check what you know

Think you have it? Try 3 quick questions and see what the article says.

1. How did the 2026 Cochrane review rate the evidence on thymosin alpha-1 for chronic hepatitis B?

Question 1 of 3

Score: 0 right, 0 of 3 answered

Is thymosin alpha-1 legal in New York?
It is not FDA-approved, it is in none of the three categories on FDA's list for state-licensed pharmacies and physicians, and FDA proposed against adding it to the pharmacy bulks list [1][2][4]. The available records do not show a separate New York law specific to it.
Is thymosin alpha-1 FDA-approved?
No. A Drugs@FDA search found no US marketing application. Four orphan drug designations are a separate process and are not approvals [1].
What is its status on FDA's compounding lists?
It is in none of the three categories for state-licensed pharmacies and physicians, and it is in category 3 for outsourcing facilities. FDA proposed against adding it to the pharmacy bulks list after a 4 yes, 17 no committee vote [2][3][4].
Where is thymosin alpha-1 approved?
FDA lists national authorisations in Italy, India and Hong Kong [1]. Two older reviews by authors tied to the developer say over 35 countries (2009) and more than 30 countries (2007) [7][8].
Is thymosin alpha-1 banned in sport?
It is not named on WADA's 2026 Prohibited List [6]. Thymosin-beta-4 and TB-500 are named under S2.3, but those are different peptides [6].

Reader questions

What people actually ask

Short answers drawn from the sources this article cites.

Is thymosin beta-4 legal?

No US legal status is given for thymosin beta-4 itself. WADA names thymosin-beta-4 and its derivatives such as TB-500 under S2.3 growth factors, and TB-500 is among the six peptides named in HHS's October 2026 draft enforcement-discretion policy. Thymosin beta-4 is a different peptide from thymosin alpha-1.

Where to inject thymosin alpha 1?

No injection site is specified for compounded or bulk thymosin alpha-1, and no US-approved dose exists. The only route described comes from Italy's label for the branded Zadaxin 1.6 mg injection: subcutaneous or intramuscular use twice weekly for 4 weeks, starting at the first vaccination. That is not a dose for compounded or bulk product, and the label says it is not for children.

Show all 10 referencesHide references
Evidence overview for Is Thymosin Alpha-1 Legal in New York? How to Access It Legally